|
Name |
Conidiogenol
|
Molecular Formula | C20H34O2 | |
IUPAC Name* |
(1R,2R,3R,5R,6R,9S,10R,14R)-2,6,11,11,14-pentamethyltetracyclo[7.6.0.01,6.010,14]pentadecane-3,5-diol
|
|
SMILES |
C[C@H]1[C@@H](C[C@H]([C@]2([C@@]13C[C@]4(CCC([C@H]4[C@@H]3CC2)(C)C)C)C)O)O
|
|
InChI |
InChI=1S/C20H34O2/c1-12-14(21)10-15(22)19(5)7-6-13-16-17(2,3)8-9-18(16,4)11-20(12,13)19/h12-16,21-22H,6-11H2,1-5H3/t12-,13-,14+,15+,16+,18+,19-,20-/m0/s1
|
|
InChIKey |
PGVUQRGISXSKPM-TVJCRXAUSA-N
|
|
Synonyms |
Conidiogenol; (-)-conidiogenol; CHEBI:189094; (1R,2R,4R,4aR,6aS,6bR,9aR,10aR)-1,4a,7,7,9a-pentamethyltetradecahydropentaleno[1,2-c]indene-2,4-diol
|
|
CAS | NA | |
PubChem CID | 11023190 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 306.5 | ALogp: | 4.9 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 40.5 | Aromatic Rings: | 4 |
Heavy Atoms: | 22 | QED Weighted: | 0.685 |
Caco-2 Permeability: | -4.805 | MDCK Permeability: | 0.00006020 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.011 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.826 |
Blood-Brain-Barrier Penetration (BBB): | 0.094 | Plasma Protein Binding (PPB): | 88.35% |
Volume Distribution (VD): | 0.932 | Fu: | 10.88% |
CYP1A2-inhibitor: | 0.031 | CYP1A2-substrate: | 0.406 |
CYP2C19-inhibitor: | 0.063 | CYP2C19-substrate: | 0.9 |
CYP2C9-inhibitor: | 0.331 | CYP2C9-substrate: | 0.763 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.446 |
CYP3A4-inhibitor: | 0.544 | CYP3A4-substrate: | 0.281 |
Clearance (CL): | 4.877 | Half-life (T1/2): | 0.321 |
hERG Blockers: | 0.242 | Human Hepatotoxicity (H-HT): | 0.126 |
Drug-inuced Liver Injury (DILI): | 0.042 | AMES Toxicity: | 0.011 |
Rat Oral Acute Toxicity: | 0.151 | Maximum Recommended Daily Dose: | 0.381 |
Skin Sensitization: | 0.844 | Carcinogencity: | 0.02 |
Eye Corrosion: | 0.911 | Eye Irritation: | 0.937 |
Respiratory Toxicity: | 0.882 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003804 | 0.532 | D0I2SD | 0.309 | ||||
ENC002545 | 0.526 | D0X7XG | 0.306 | ||||
ENC003581 | 0.519 | D0L2LS | 0.305 | ||||
ENC002547 | 0.457 | D0Z1XD | 0.290 | ||||
ENC004410 | 0.439 | D0U3GL | 0.290 | ||||
ENC002546 | 0.422 | D0Q6NZ | 0.289 | ||||
ENC002221 | 0.417 | D03XOC | 0.286 | ||||
ENC005300 | 0.417 | D0P0HT | 0.284 | ||||
ENC002539 | 0.417 | D03ZTE | 0.271 | ||||
ENC003219 | 0.415 | D0G3SH | 0.271 |